The U.S. Food and Drug Administration has given another approval for a drug from Indianapolis-based Eli Lilly and Co. The approval for Cyramza is for the treatment of patients with hepatocellular carcinoma, the most common form of liver cancer.
The approval is the fifth for Cyramza and the FDA has also removed the boxed warning from the drug’s labeling. The treatment, which is administered through an injection, is given to patients who have reached a particular biomarker and have been treated with another drug, sorafenib.